Watch INO. Know when insiders buy.
One email the day a filing lands. Free.
INO
INOVIO PHARMACEUTICALS, INC.
1.21
+0.06 +5.22%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
59
WATCH · shorts 59
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $125.1MP/E —DIV YIELD —FCF YIELD -64.57%REV TTM $0 −100.0%NET INCOME −$67.4MNET DEBT $31.2M52W 0.66 – 2.65SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$18.6M | −$6M | — | -0.07 | −$18M | $0 | −$18M | Aug 12 |
| Q1 2026 · Mar 31 | $0 | −100.0% | — | −$21.9M | −$19.7M | — | -0.28 | −$21.6M | $0 | −$21.6M | Aug 12 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$17.5M | $3.8M | — | 0.31 | −$19.4M | $127K | −$19.5M | Mar 12 |
| Q3 2025 · Sep 30 | $0 | — | — | −$21.2M | −$45.5M | — | -0.87 | −$21.6M | $68K | −$21.6M | Nov 10 |
| Q2 2025 · Jun 30 | $0 | −100.0% | — | −$23.1M | −$23.5M | — | -0.61 | −$20.8M | $31K | −$20.8M | Aug 12 |
| Q1 2025 · Mar 31 | $65K | — | — | −$25.1M | −$19.7M | — | -0.51 | −$26.9M | $59K | −$26.9M | Aug 12 |
| Q4 2024 · Dec 31derived | $117K | +14.0% | — | −$20.4M | −$19.4M | — | -0.60 | −$19.7M | $0 | −$19.7M | Mar 12 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$27.3M | −$25.2M | — | -0.89 | −$27.4M | $0 | −$27.4M | Nov 10 |
| Q2 2024 · Jun 30 | $101K | — | — | −$33.2M | −$32.2M | — | -1.19 | −$28.2M | $452K | −$28.7M | Nov 10 |
| Q1 2024 · Mar 31 | $0 | — | — | −$31.5M | −$30.5M | — | -1.31 | −$28.8M | $36K | −$28.8M | Nov 10 |
| Q4 2023 · Dec 31derived | $103K | — | — | −$27.4M | −$25M | — | -1.08 | −$26.3M | $0 | −$26.3M | Mar 18 |
| Q3 2023 · Sep 30 | $388K | — | — | −$35.6M | −$33.9M | — | -1.52 | −$29.1M | $0 | −$29.1M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $65K | — | −$86.8M | −$84.9M | -130000.0% | -1.81 | −$88.6M | $286K | −$88.9M | — | — |
| FY2024 · to Dec 31 | $218K | — | −$112.4M | −$107.3M | -49254.3% | -3.95 | −$104.1M | $488K | −$104.6M | — | — |
| FY2023 · to Dec 31 | $832K | — | −$143.9M | −$135.1M | -16239.9% | -6.09 | −$124.4M | $321K | −$124.7M | — | — |
| FY2022 · to Dec 31 | $10.3M | — | −$267.6M | −$279.8M | -2726.7% | -14.07 | −$216.2M | $969K | −$217.2M | — | — |
| FY2021 · to Dec 31 | $1.8M | — | −$301.2M | −$303.7M | -17109.9% | -17.45 | −$215.7M | $1.2M | −$216.9M | — | — |
| FY2020 · to Dec 31 | $7.4M | — | −$124.1M | −$166.4M | -2245.4% | -1.07 | −$178M | $1.5M | −$179.5M | — | — |
Every number comes from INOVIO PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.